多糖硫酸化修饰和多糖硫酸酯的研究进展

硫酸多糖是一类糖羟基上带有硫酸根的多糖,包括从植物中提取的各种硫酸多糖、肝素、天然多糖的硫酸衍生物及人工合成的各种硫酸多糖。硫酸多糖具有抗病毒、抗肿瘤、抗凝血和增强免疫等生物活性,为提高中药多糖的生物活性,可通过硫酸化修饰的方法进行结构改造,获取多糖硫酸酯。本文就多糖的硫酸化修饰方法、多糖硫酸酯的生物学活性及其影响因素、作用机制和临床应用进行了综述。     

LC－CW的抗肿瘤作用及其机理的研究

提取干酪乳酸杆菌细胞壁成分（ＬＣ－ＣＷ）,研究其抗肿瘤作用及其机理。结果表明：１００μｇＬＣ－ＣＷ,ｉｐ,连续４天,可明显抑制小鼠Ｓ１８腹水瘤移植物的生长,抑瘤率为５４％。增强ＩＬ－２诱导的ＬＡＫ杀伤活性,可明显促进小鼠ＮＫ杀伤活性,明显促进小鼠Ｔ细胞转化,促进ＣｏｎＡ和ＰＨＡ－Ｐ诱导的ＩＬ－２产生,促进ＳＩＬ－２Ｒ的减少。研究结果表明ＬＣ－ＣＷ是一种重要的抗肿瘤免疫调节因子。     

食药用真菌多糖对肿瘤免疫逃逸调节作用机制研究进展

食药用真菌多糖是食药用真菌的主要天然生物活性成分,可以从多层次、多靶点调节机体的免疫功能,被认为是一种天然免疫调节剂。此前食药用真菌多糖抗肿瘤机制研究集中在提升机体的免疫力达到抑制肿瘤的目的,但近年的研究表明它可以调节肿瘤微环境,恢复机体对肿瘤以及肿瘤微环境的监视能力,提升机体对肿瘤微环境的特异性免疫应答能力,进而达到充分发挥其抑制和杀伤肿瘤的功能。我们课题组前期研究中也发现食药用菌多糖可以正向调节肿瘤小鼠外周血免疫细胞数量,促进免疫细胞浸润到肿瘤微环境中帮助机体识别及杀伤肿瘤细胞,改善肿瘤微环境免疫状态。本文在我们团队的研究工作的基础上,结合国内外文献总结食药用真菌多糖作为免疫调节剂在抑制肿瘤免疫逃逸中的生物活性,结合肿瘤微环境探讨其与肿瘤免疫的关系、作用机制和在肿瘤治疗中的作用,以期为食药用真菌多糖免疫治疗提供新思路。     

灵芝多糖抗肿瘤作用的免疫分子机制研究

灵芝多糖是一种从灵芝实体中被提取出来的多糖组份,灵芝多糖极易溶于水。很多科学研究表明,灵芝多糖具有一定的免疫调节功能以及一定的抗肿瘤等作用,并且认为在体外灵芝多糖并没有直接的对肿瘤细胞有抑制作用或者杀伤作用,反而在体内灵芝多糖则具有很好的抗肿瘤作用。所以,通常情况下,对灵芝多糖的抗肿瘤作用的研究主要就是通过增加免疫功能,尽管我国很多科学家已经从免疫功能的角度对灵芝多糖的抗肿瘤作用进行研究,但确切的机制并没有明确。因此文章结合具体实验对灵芝多糖的抗肿瘤作用的免疫分子机制进行深入研究。     

甘草多糖的抗肿瘤活性及对免疫功能的影响

从甘草残渣中提取分离得到甘草多糖,采用血清溶血素及抗体生成细胞水平实验、碳粒廓清实验、S180荷瘤小鼠实验测定其免疫和抗肿瘤作用.结果表明,甘草多糖能促进小鼠血清溶血素IsM和ISG的生成,提高抗体生成细胞水平和胸腺、脾脏指数,增强巨噬细胞的吞噬活性,抑制肿瘤细胞S180的生长,与对照组比较均有显著性差异,提示甘草多糖具有免疫增强和肿瘤抑制作用.     

昆布多糖硫酸酯化修饰及抗肿瘤活性的研究

对昆布多糖进行硫酸酯化修饰,考察修饰前后多糖结构及抗肿瘤活性的变化。采用氯磺酸-吡啶法进行多糖硫酸酯化修饰,考察了昆布多糖及其硫酸酯的红外光谱、核磁光谱特征,扫描电镜观察了表面形态,采用MTT比色法进行抗肿瘤活性评价。结果表明,昆布多糖及其硫酸酯都具有典型的多糖红外吸收,昆布多糖硫酸酯具有硫酸基的特征吸收峰;昆布多糖及其硫酸酯均是以β-(1→3)糖苷键为主链的多糖,昆布多糖硫酸酯的硫酸基取代位置在C2-OH与C6-OH。昆布多糖及其硫酸酯表面立体形态差异显著,昆布多糖表面呈云雾状或海绵状,昆布多糖硫酸酯表面呈片状或块状。昆布多糖及其硫酸酯对人肠癌细胞LOVO生长都具有明显的抑制作用,并且昆布多糖硫酸酯的抗肿瘤作用强于昆布多糖。     

LC—CW的抗肿瘤作用及其机理的研究

提取干酪乳酸杆菌细胞壁成分,研究其抗肿瘤作用及其机理。结果表明：１００μｇ－ＬＣ－ＣＷ,ｉｐ,连续４天,可明显抑制小鼠Ｓ１８０腹水瘤移植物的生长,抑瘤率为５４％。增强ＩＬ－２诱导的ＬＡＫ杀伤活性。可明显促进小鼠ＮＫ杀伤活性,明显促进小鼠Ｔ细胞转化,促进ＣｏｎＡ和ＰＨＡ－Ｐ诱导的ＩＬ－２产生,促进ＳＩＬ－２Ｒ的减少。     

硒对肝癌细胞凋亡作用的研究

在小鼠右腋皮下接种Ｈ２２肿瘤细胞悬液,灌服含硒液（硒酸酯多糖）有抑制皮下肿瘤块生长的作用,在人肝癌细胞株培养液中,加入一定浓度含硒液（２０μｇ／ｍｌ、５０μｇ／ｍｌ、１５０μｇ／ｍｌ）,能抑制肝癌细胞增殖,并促使细胞凋亡。与此同时,小鼠血液中谷胱甘肽过氧化物酶（ＧＳＨ－Ｐｘ）活性提高,血浆和细胞培养液中ＮＯ含量升高。探讨硒酸脂多糖引起肝癌细胞凋亡,可能与使抗氧化活性提高、阻遏自由基对癌细胞增殖的介导及促使ＮＯ释放增加有关。     

用自旋捕集技术研究硒化合物对活性氧自由基的清除作用

亚硒酸钠,硒代甲硫氨酸和硒代硫酸软骨素对黄嘌呤氧化酶体系和人多形核白细胞（ＰＭＮ）呼吸暴发时产生的超氧阴离子（Ｏ）自由基;和Ｆｅｎｔｏｎ反应生成的羟自由基（·ＯＨ）有明显的清除作用,并抑制ＰＭＮ呼吸暴发时对氧的消耗。实验结果说明不同硒化合物不仅能够清除细胞体系产生的活性氧自由基,而且对化学反应生成的活性氧自由基也有清除作用。     

肾透明细胞癌中免疫检查点相关的免疫逃逸机制的研究进展

摘要：近年来,免疫治疗在晚期肾透明细胞癌的治疗中异军突起,使人们对于肾癌治疗有了全新的认识。肿瘤免疫治疗药物是通过抑制免疫检查点从而抑制肿瘤细胞免疫逃逸,使免疫细胞可以杀伤肿瘤细胞来发挥治疗作用。因此,了解肾透明细胞癌中免疫检查点相关免疫逃逸机制对于制定有效的治疗策略以及开发新的免疫治疗药物至关重要。本文对目前肾透明细胞癌中主要的免疫检查点（PD-1/PD-L1、CTLA-4、B7-H4、LAG-3、TIM-3和HLA-G）相关的免疫逃逸机制进行综述。     

In vivo generation of lymphokine activated killer cell activity by ABPP and interleukin-2 and their antitumor effects against immunogenic and nonimmunogenic tumors in murine tumor models

Summary The capacity of the interferon inducer ABPP and recombinant interleukin-2 (IL-2) to generate lymphokine activated killer (LAK) cell activity in vivo was examined and compared to the cytolysis of fresh tumor cells by in vitro generated LAK cells. Various tumors differing in histology and immunogenicity were used in in vitro and in vivo experiments. The i.p. administration of ABPP or IL-2 generated much higher levels of LAK cell activity in the peritoneal exudate than in the spleen. Administration of 2 injections of ABPP was as effective as a 3-day course of moderate doses of IL-2. Generation of LAK cell activity by IL-2 was dose dependent. ABPP had significant antitumor activity in vivo in both the i.p. tumor model and the pulmonary metastasis model when administered early (24–48 h after tumor inoculation), but was ineffective against established (day 3) tumor or advanced grossly visible i.p. (day 8) tumor. Treatment of established tumor with IL-2 and LAK cells was not more effective when ABPP was given concurrently. In contrast when ABPP preceded IL-2 and LAK treatment an additional antitumor effect was seen. Immunogenic tumors were more sensitive to treatment with ABPP than nonimmunogenic tumors. Only a marginal difference in lysability in vitro existed. The antitumor effects of ABPP in vivo may therefore be mediated by mechanisms other than cytolysis by activated killer cells alone. These data taken together suggest that ABPP and IL-2 induce discernable levels of LAK cell activity, but do not synergize when combined     

番茄红素与癌

番茄红素是主要的类胡萝卜素之一,最近的科学研究发现,它对人类健康有重要的作用。本文介绍了番茄红素的食物来源、生物合成、物理化学特性和生理活性,它的抗癌效果与其抗氧化活性有关。很多的流行病学研究证明,番茄红素对一些类型的癌有预防效果,如前列腺癌和消化道癌。体内和体外的癌细胞培养研究也支持这一结论。因此,具有广泛用途的番茄红素,将有希望成为最重要的一个化学防癌物质。     

The in vitro and in vivo antiviral effects of salidroside from Rhodiola rosea L. against coxsackievirus B3

The aim of this study was to investigate the antiviral effects of salidroside, a major component of Rhodiola rosea L. First, the antiviral effects of salidroside against coxsackievirus B3 (CVB3) were determined in vitro and in vivo. Then, the effect of salidroside on the mRNA expression of some important cytokines was measured in hearts of infected BALB/c mice by RT-PCR. Salidroside exhibited obvious antiviral effects both in in vitro and in vivo experiments. Salidroside was found to modulate the mRNA expression of interferon-gamma (IFN-gamma), interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-alpha), and interleukin-2 (IL-2). In conclusion, salidroside possesses antiviral activities against CVB3 and it may represent a potential therapeutic agent for viral myocarditis.     

IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase

IL-22 is a recently discovered cytokine of the IL-10 family that binds to a class II cytokine receptor composed of IL-22R1 and IL-10R2(c) and influences a variety of immune reactions. As IL-22 has also been shown to modulate cell cycle and proliferation mediators such as ERK1/2 and JNK, we studied the role of IL-22 in proliferation, apoptosis, and cell cycle regulation in EMT6 murine breast cancer cells in vitro and in vivo. In this study, we report that murine breast cancer cells express functional IL-22R as indicated by RT-PCR studies, immunoblotting, and STAT3 activation assays. Importantly, IL-22 exposure of EMT6 cells resulted in decreased levels of phosphorylated ERK1/2 and AKT protein kinases, indicating an inhibitory effect of IL-22 on signaling pathways promoting cell proliferation. Furthermore, IL-22 induced a cell cycle arrest of EMT6 cells in the G(2)-M phase. IL-22 reduced EMT6 cell numbers and the proliferation rate by approximately 50% as measured by [(3)H]thymidine incorporation. IL-22 treatment of EMT6 tumor-bearing mice lead to a decreased tumor size and a reduced tumor cell proliferation in vivo, as determined by 3'-deoxy-3'-fluorothymidine-positron emission tomography scans. Interestingly, IL-22 did not induce apoptosis, as determined in annexin V binding assay and caspase-3 activation assay and had no effect on angiogenesis in vivo. In conclusion, our results indicate that IL-22 reduced tumor growth by inhibiting signaling pathways such as ERK1/2 and AKT phosphorylation that promote tumor cell proliferation in EMT6 cells. Therefore, IL-22 may play a role in the control of tumor growth and tumor progression.     

Mechanism of action of cyclosporin A in vivo. I. Cyclosporin A fails to inhibit T lymphocyte activation in response to alloantigens

Although cyclosporin A (Cy A) has been widely used clinically as a potent suppressor of organ allograft rejection and has been shown to block T lymphocyte activation in vitro by inhibiting the generation of interleukin 2 (IL-2) and other lymphokines, little direct evidence is available to support the view that the immunosuppressive effects of Cy A in vivo are mediated by a similar inhibition of the autocrine lymphokine cascade. We have used a quantitative assay for the assessment of the role of the IL-2/IL-2 receptor system in the activation of the draining popliteal lymph node population after the injection of allogeneic cells in the footpad to define the effects of Cy A on the early events of lymphocyte activation in vivo and to compare them with the effects of Cy A on lymphocyte activation in vitro. The administration of Cy A in vivo had no effect on alloantigen-induced increases in cell size, percentage of cells expressing the IL-2 receptor, the spontaneous or IL-2-driven proliferation of freshly explanted cells, or the induction of cytotoxic T lymphocyte activity. These findings raise major questions about the mechanism of action of Cy A in vivo and suggest that more experimentation is required to probe the mechanisms of Cy A-induced suppression of the response to allografts.     

IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production

The common gamma-chain cytokine, IL-21, is produced by CD4(+) T cells and mediates potent effects on a variety of immune cells including NK, T, and B cells. NKT cells express the receptor for IL-21; however, the effect of this cytokine on NKT cell function has not been studied. We show that IL-21 on its own enhances survival of NKT cells in vitro, and IL-21 increases the proliferation of NKT cells in combination with IL-2 or IL-15, and particularly with the CD1d-restricted glycosphingolipid Ag alpha-galactosylceramide. Similar to its effects on NK cells, IL-21 enhances NKT cell granular morphology, including granzyme B expression, and some inhibitory NK receptors, including Ly49C/I and CD94. IL-21 also enhanced NKT cell cytokine production in response to anti-CD3/CD28 in vitro. Furthermore, NKT cells may be subject to autocrine IL-21-mediated stimulation because they are potent producers of this cytokine following in vitro stimulation via CD3 and CD28, particularly in conjunction with IL-12 or following in vivo stimulation with alpha-galactosylceramide. Indeed, NKT cells produced much higher levels of IL-21 than conventional CD4 T cells in this assay. This study demonstrates that NKT cells are potentially a major source of IL-21, and that IL-21 may be an important factor in NKT cell-mediated immune regulation, both in its effects on NK, T, and B cells, as well as direct effects on NKT cells themselves. The influence of IL-21 in NKT cell-dependent models of tumor rejection, microbial clearance, autoimmunity, and allergy should be the subject of future investigations.     

The BCL1 B lymphoma responds to IL-4, IL-5, and GM-CSF

Proliferation in vitro of the in vivo passaged murine B cell tumor line BCL1 has been used as a standard assay for mouse interleukin-5 (IL-5) for a number of years. We demonstrate that this line will also respond to human IL-5. The response to murine IL-5 is abrogated by transforming growth factor-beta and to a lesser extent by interferon-gamma. This suggests a possible regulatory role for these lymphokines in the proliferation of B cells induced by IL-5. Other purified recombinant lymphokines were also tested for their ability to induce BCL1 proliferation. The lymphokines IL-1, IL-2, IL-3, and IL-6 had no effect on the growth of BCL1. In contrast, IL-4 and more surprisingly granulocyte-macrophage colony-stimulating factor (GM-CSF) also induced proliferation of this cell. These effects could be inhibited by specific antibodies directed against the respective lymphokines. These data suggest that GM-CSF, as well as IL-4 and IL-5, may be yet another regulator of neoplastic and possibly even normal B-cell growth and differentiation.     

Pulmonary immunity to viral infection: adenovirus infection of lung dendritic cells renders T cells nonresponsive to interleukin-2

Adenovirus (Ad) infection has been identified as predisposing hosts to the development of pulmonary disease through unknown mechanisms. Lung dendritic cells (DCs) are vital for initiating pulmonary immune responses; however, the effects of Ad infection on primary lung DC have not been studied. In contrast to the effects on bone marrow- and monocyte-derived DCs, the current study shows that Ad infection of murine BALB/c lung DCs in vitro and in vivo suppresses DC-induced T-cell proliferation. The effect of Ad on DCs was not due to a downregulation of major histocompatibility complex or costimulatory molecules. Analysis of the production of interleukin-12 (IL-12), alpha interferon (IFN-alpha), and IFN-gamma by the Ad-infected DCs shows no significant differences over noninfected control lung DCs. Ad-induced suppression was not due to a deficiency of IL-2 or other DC-secreted factors and was dependent on viral protein synthesis, as UV irradiation of Ad abrogated the suppressive effect. Results suggest that Ad-infected DCs induce T cells to be nonresponsive to IL-2 during primary coculture, as the addition of IL-2 in secondary cultures recovered T-cell proliferation. In vivo studies supported in vitro results showing that Ad infection resulted in lung T cells with decreased proliferative ability. This study demonstrates that Ad infection induces local immunoincompetence by altering DC-T-cell interactions.     

Tributyrin enhances the cytotoxic activity of interleukin-2/interleukin-12 stimulated human natural killer cells against LS 174T colon cancer cells in vitro

Tributyrin has been shown to be cytostatic to tumor cells by inducing differentiation and apoptosis. On the other hand, immunological NK cells can kill tumor cells, particularly when stimulated with interleukin-2 (IL-2) and/or interleukin-12(IL-12). However, little is known about whether and how both antitumor mechanisms act together, although in vivo such an interaction must exist. Here we demonstrate in vitro, that pretreatment of human LS 174T colon cancer cells with nontoxic concentrations of tributyrin augments the sensitivity to spontaneous NK cell activity two-fold. However, when NK cells have been activated with an optimized combination of IL-2 and IL-12, the immunocytotoxicity increases up to five-fold (from 14% to 70%), versus a 3.8-fold increase against untreated cancer cells. These effects are accompanied by increased IFN-γ secretion and decreased TGF-β₁ secretion. Tributyrin is found to be a potent inducer of ICAM-1, LFA-3 and Fas on target cells corresponding to an increase of the FasL expression by IL-2/IL-12 on the effector cells. Our data suggest a synergistic link between induction of tumor cell differentiation and immunological defense mechanisms that may provide a rational basis for the improvement of clinical protocols, especially for colon cancer. Received: 6 November 2000 / Accepted: 15 December 2000